Friday, 14 December 2018

Zydus Cadila gets USFDA nod for acne treatment topical solution

19 July 2018 | News

The company has received approval from the US Food and Drug Administration (USFDA) to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1 per cent, Zydus Cadila said in a BSE filing.

Image Source: Pixabay

Image Source: Pixabay

Drug firm Zydus Cadila has said that it has received final approval from the US health regulator to market Clindamycin Phosphate Topical Solution, used to treat acne.

The company has received approval from the US Food and Drug Administration (USFDA) to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1 per cent.

Clindamycin is an antibiotic which works by stopping the growth of bacteria. It is used to treat acne and helps to decrease the number of acne lesions.

The company said it will manufacture the product at the group's topical manufacturing facility in Ahmedabad.

The company has more than 204 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Does Indian Pharma lack an innovation-friendly ecosystem?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls